Skip to main navigation

Skip to content

Side Menu

About Us
Our Platform
Our Programs
Patients and Physicians
Inside Seres
Investors and News
Contact Us

Press Releases

Seres' news, events and other information can be found throughout the pages below.

Investor Relations

Stock Information
News and Events
- Press Releases
- Events & Presentations
Financial Information
- SEC Filings
- Annual Reports
Corporate Governance
Shareholder Services

Press Releases

Keyword Search

Year

May 28, 2020

Seres Therapeutics to Present at Jefferies Virtual Healthcare Conference

May 18, 2020

Seres Therapeutics to Host Virtual SER-109 Focused Symposium on May 27, 2020, Ahead of Phase 3 ECOSPOR III Study Read-Out

May 07, 2020

Seres Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates

Apr 30, 2020

Seres Therapeutics to Host First Quarter 2020 Financial Results and Operational Progress Conference Call on May 7, 2020

Apr 06, 2020

Seres Therapeutics Appoints Lisa von Moltke, M.D., as Chief Medical Officer

Mar 30, 2020

Seres Therapeutics Announces Completion of Enrollment in SER-109 Phase 3 ECOSPOR III Study for Recurrent Clostridium difficile Infection and Provides Clinical Pipeline Updates

Mar 23, 2020

Seres Therapeutics Appoints Paul Biondi, Experienced Biopharmaceutical Strategy and Corporate Development Professional, to Its Board of Directors

Mar 15, 2020

Seres Therapeutics to Virtually Present at the Chardan Microbiome Medicines Summit

Mar 13, 2020

Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration’s March 12, 2020 Safety Alert Related to Use of Fecal Microbiota Transplantation

Mar 02, 2020

Seres Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Highlights

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Shareholder Tools

RSS Feeds
E-mail Alerts
Print

© 2020 Seres Therapeutics.

Footer Left Menu

Privacy Policy
Terms of Use

Follow us on Linkedin
Follow us on Twitter
Follow us on Facebook